Title
Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem.

Permalink
https://escholarship.org/uc/item/20q9j9pk

Journal
Transactions of the Royal Society of Tropical Medicine and Hygiene, 115(3)

ISSN
0035-9203

Authors
Blumberg, Seth
Borlase, Anna
Prada, Joaquin M
et al.

Publication Date
2021-03-01

DOI
10.1093/trstmh/traa170

Peer reviewed
Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem

Seth Blumberg, Anna Borlase, Joaquin M. Prada, Anthony W. Solomon, Paul Emerson, Pamela J. Hooper, Michael S. Deiner, Benjamin Amoah, T. Déirdre Hollingsworth, Travis C. Porco, and Thomas M. Lietman

Background: Progress towards elimination of trachoma as a public health problem has been substantial, but the coronavirus disease 2019 (COVID-19) pandemic has disrupted community-based control efforts.

Methods: We use a susceptible-infected model to estimate the impact of delayed distribution of azithromycin treatment on the prevalence of active trachoma.

Results: We identify three distinct scenarios for geographic districts depending on whether the basic reproduction number and the treatment-associated reproduction number are above or below a value of 1. We find that when the basic reproduction number is $<1$, no significant delays in disease control will be caused. However, when the basic reproduction number is $>1$, significant delays can occur. In most districts, 1 y of COVID-related delay can be mitigated by a single extra round of mass drug administration. However, supercritical districts require a new paradigm of infection control because the current strategies will not eliminate disease.

Conclusions: If the pandemic can motivate judicious, community-specific implementation of control strategies, global elimination of trachoma as a public health problem could be accelerated.

Keywords: control, COVID-19, elimination, mass drug administration, mathematical modelling, trachoma

Introduction

Trachoma remains a major cause of preventable blindness, particularly in sub-Saharan Africa. Substantial reduction in the global prevalence of trachoma has been achieved, but the coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented disruption of public health programs that combine surveillance of disease transmission with treatment for endemic districts. Since transmission cannot be measured directly, the World Health Organization (WHO) recommends monitoring trachoma by assessing the prevalence of trachomatous inflammation–follicular (TF) in the upper tarsal conjunctiva of children 1–9 y of age.1,2 For elimination of trachoma as a public health problem (termed trachoma ‘control’ herein), the WHO requirements include that the prevalence of TF in children be reduced to $<5\%$ in each formerly endemic district. One cornerstone of trachoma control is annual mass drug administration (MDA) of azithromycin to endemic districts.3 The pandemic is delaying regular MDA and thus allowing possible resurgence of active trachoma in some districts.

Trachoma is caused by repeated conjunctival infection with ocular strains of Chlamydia trachomatis.4 The bacterium is spread by direct contact from infectious individuals, fomites or flies that land on human eyes.5 Repeated infection causes inflammation of the conjunctiva that may then progress to scarring, subsequent in-turning of the eyelid and eventual irreversible destruction of the cornea.6 Fortunately there has been considerable progress towards elimination of trachoma as a public health problem, in line with targets set and partnerships fostered within the WHO Alliance for the Global Elimination of Trachoma by the year 2020 (GET2020). A strategy of surgery for advanced disease, mass
administration of antibiotics, facial cleanliness and environmental improvement (the SAFE strategy) has been advocated by the GET2020 alliance. This approach is supported by randomized clinical trials that have demonstrated the efficacy of antibiotic therapy for reducing the prevalence of infection and inflammatory disease and the efficacy of surgery to reposition damaged eyelids.\(^7\)\(^8\) Because of these interventions, as well as the possible indirect benefit of other public health measures, 10 countries have now been validated by the WHO as having eliminated trachoma as a public health problem.\(^9\)

Based on their intensity of transmission, we can categorize districts as subcritical, MDA-subcritical or supercritical. We delineate these levels of transmission by the basic reproduction number, \(R_0\), and the treatment-associated reproduction number, \(R_t\). We define \(R_0\) as the mean number of secondary infections each infection causes without intervention and in the absence of immunity of close contacts and \(R_{\text{effective}}\) as the mean number of secondary infections each infection causes in the presence of immunity.\(^10\)

We define \(R_t\) as the mean number of new infections caused by each case in a district that is receiving annual, community-wide MDA with azithromycin. We define subcritical districts as those with \(R_0 < 1\) and thus control of trachoma would be anticipated regardless of MDA. We define MDA-subcritical districts as those with \(R_0 > 1\), but \(R_t < 1\). These districts are progressing towards control, but only because of ongoing annual MDA. Finally, we define supercritical districts as those where both \(R_0\) and \(R_t\) are \(> 1\). These districts are not expected to achieve control, despite ongoing annual MDA. Our definitions of subcritical, MDA-subcritical and supercritical transmission roughly correspond to how other manuscripts describe hypoendemic, mesoendemic and hyperendemic settings, respectively.\(^11\)

Here we utilize a mathematical model of trachoma transmission to evaluate how the disruption of MDA due to the COVID-19 pandemic may delay progress towards trachoma control.

**Methods**

To simulate the prevalence of trachoma infection and estimate the delay in control caused by the COVID-19 pandemic we developed a simple model for trachoma transmission among children. We assume that children form a core group for transmission and that transmission from adults to children is negligible.\(^12\) Although the relative importance of different routes of transmission are still debated, it is commonly accepted that infection occurs by transfer of ocular *C. trachomatis* between uninfected children and infected children.\(^13\)\(^14\) Thus transmission can be modelled according to the mass-action assumption of the classical susceptible-infected model. In particular, infection prevalence is measured in children only and new infections occur at a rate that is proportional to the product of the fraction of children that are susceptible to infection and the fraction of children infected.\(^15\)\(^16\) Recovery from infection occurs at a rate that is proportional to the prevalence of infection. Once an infection clears, children become susceptible to infection again. Whenever a district receives a round of MDA, the number of infected people is reduced by the ‘overall MDA efficacy’, which we define as the product of azithromycin coverage and the probability that azithromycin clears infection from an individual. For Figures 1–3, we assume that the average duration of infection for children is 6 months, the antibiotic coverage is 80% and the azithromycin clearance is 87.5%.\(^16\)

Based on the preceding susceptible–infected–susceptible model, trachoma control efforts are represented by periods of exponential growth (or decay) of infection that are separated by periodic reductions in infection due to annual MDA (Figure 1, red curve). The direction of exponential growth or decay is dependent on \(R_0\), with values of \(R_0 < 1\) indicating decay and \(R_0 > 1\) indicating growth. The specific exponential rate depends on \(R_{\text{effective}}\), which is the product of \(R_0\) and the proportion of the population that is not infected and not immune. We define the program delay as the time that an MDA cycle is delayed due to circumstances such as the COVID-19 pandemic (Figure 1, aqua curve). We define the control delay as the time gap between the beginning of MDA disruption and a return to the prevalence of infection prior to the disruption. By reflecting the additional time it will take for district-level control to be achieved, the control delay represents the overall consequence of a program delay.

We consider three scenarios for MDA. In the scenario labelled ‘MDA as planned’, one distribution of MDA occurs each year. In the scenario labelled ‘MDA disrupted’, one of the annual MDA cycles is missed. In the scenario labelled ‘MDA catch-up’, a cycle of annual MDA is missed and then a subsequent year has an additional MDA. We term this additional MDA as a ‘catch-up MDA’.

When using our model to estimate the control delay, we make the approximation that the change in prevalence between MDA time points follows an exponential curve. This is equivalent to assuming that the number of susceptible individuals is constant rather than that the entire population is constant. We acknowledge that this assumption does not hold well for districts that are close to equilibrium, such as supercritical districts or districts that have not yet received MDA. See the supplementary material (Text S1) for more methodological details.

**Results**

The impact of a 1-y program delay differs depending on whether transmission is subcritical, MDA-subcritical or supercritical (Figure 2 and Table 1). In subcritical districts, the control delay is less than the program delay since prevalence is decreasing even in the absence of annual MDA. In MDA-subcritical districts, the control delay is longer than the program delay, but resumption of annual MDA cycles will put a district back on track for eventual control. An additional catch-up MDA would return a district to its original time course, resulting in a control delay close to zero. In supercritical districts, a program delay followed by resumption of the regular MDA schedule would be roughly equivalent, but not lead to control. In contrast, a program delay followed by a catch-up MDA could accelerate control in supercritical districts.

Our model predicts that a program can get back on track if multiple MDA cycles are missed, provided that extra MDA cycles can be provided in subsequent years. For example, a program could get back on track after missing two annual MDA cycles if it had the resources to provide semi-annual MDAs for 2 y before resuming annual MDA. The exact timing of catch-up MDA does not matter. For example, the extra treatments could be 1, 3 or even 6 months after the scheduled annual MDA (supplementary material Text S1).
Our model predicts the control delay increases as the program delay or $R_{\text{effective}}$ increases (Figure 3). Since $R_{\text{effective}}$ decreases as the infection prevalence increases, this implies that the control delay is higher when MDA disruption occurs after a district has had multiple rounds of treatment. For our estimates of MDA coverage and efficacy, the threshold value for $R_{\text{effective}}$ that differentiates MDA-subcritical and supercritical transmission is 1.6. As $R_{\text{effective}}$ approaches that critical point, the duration of the control delay becomes increasingly large. The theoretical delay becomes infinite for supercritical transmission. This is a reflection that supercritical districts will require new treatment strategies in order to achieve trachoma control, even had there not been a disruption in the annual MDA schedule.

Although the prevalence of TF in any given year does not provide a direct measurement of $R_{\text{effective}}$, $R_0$ or $R_1$, the trend of TF over time is related to these values. An important implication for TF surveillance is that our model of infection prevalence does not reflect the time course of TF itself. This is because TF is not a perfect marker of current infection, but rather a lagging indicator caused by the inflammatory response to infection. Thus TF prevalence surveys may not register the impact of decreased infection prevalence for 6–12 months.

Estimates of the duration of infection in children have ranged from $<10$ weeks to $>1$ y. In addition the overall efficacy of MDA to decrease infection in the immediate post-treatment period is unknown. Sensitivity analyses show that for subcritical districts, the control delay increases as the duration of infection increases (supplementary material Figure S1, top panel). In contrast, for MDA-subcritical districts, the control delay decreases as the duration of infection increases. The same qualitative features can be seen for the impact of the overall MDA efficacy on the control delay (supplementary material Figure S1, bottom panel).

**Discussion**

Our model provides a quantitative perspective on how trachoma control is impacted by MDA disruption as a consequence of the COVID-19 pandemic. Interpretation of our results in the context of findings from randomized controlled trials (RCTs) provides a framework for strategizing the effective distribution of future MDA. Recommended strategies for maintaining progress towards trachoma control vary based on whether a region is subcritical, MDA-subcritical or supercritical.
Figure 2. Modelling scenarios. Each panel corresponds to a different level of transmission, as defined by whether $R_0$ and $R_T$ are $>1$ or $<1$ (Table 1). The layout of each panel is similar to Figure 1. Within each panel the ‘MDA as planned’ scenario corresponds to no disruption of annual MDA. The ‘MDA disrupted’ scenario corresponds to a 1-y disruption starting at year 1.0 and includes skipping one annual MDA cycle at year 1.5. The ‘MDA catch-up’ scenario involves giving an extra MDA at year 3 after skipping an annual MDA at year 1.5. Between MDA cycles, the transmission dynamics are determined by a susceptible–infected–susceptible model (see Methods for details). For visual clarity, the time series corresponding to the scenarios are slightly offset horizontally. An $R_0$ of 0.95, 1.5 and 2.5 are assumed for subcritical, MDA-subcritical and supercritical transmission, respectively. At the time of MDA disruption (year 1.0), the infection prevalence of the three transmission scenarios is 0.06, 0.13 and 0.36, respectively. This corresponds to an $R_{\text{effective}}$ of 0.89, 1.30 and 1.61, respectively.

In subcritical districts, infection is difficult to detect, and RCTs have shown that trachoma may be controllable without multiple rounds of MDA. The empirical observation of self-contained transmission in subcritical districts is consistent with our model's prediction that a program delay in MDA will not lead to a noticeable delay for district-level control. The rare apparent resurgence reported from a few subcritical districts may be attributable to a combination of misclassification and measurement error.

In MDA-subcritical districts, our model suggests that the delay in achieving control will be longer than the program delay. Our model is also consistent with other modelling studies that indicate a missed cycle of MDA can be mitigated by a single catch-up MDA. In addition, the exact timing of the catch-up MDA does not significantly affect the performance.

In supercritical districts, the control delay can vastly exceed any delay due to COVID-19. This finding aligns with prior trials and models that show infection returns more rapidly after MDA in supercritical districts. Some of these districts may eventually head towards control due to subtle reductions in disease transmission caused by changes in socio-economic factors. However, in the limited number of districts where TF remains $>30\%$ after a decade of MDA, our model suggests that transmission is so

| Transmission         | $R_0$ | $R_T$ | Control delay                        | Catch-up MDA restores progress |
|----------------------|-------|-------|-------------------------------------|-------------------------------|
| Subcritical          | $<1$  | $<1$  | Less than program delay             | Yes                           |
| MDA-subcritical      | $>1$  | $<1$  | Greater than program delay          | Yes                           |
| Supercritical        | $>1$  | $>1$  | Not applicable, as control will not be achieved | Yes                           |
efficacious that annual MDA will not lead to control even if there is no disruption to azithromycin distribution. Thus alternative strategies need to be considered for control to be achieved in the near future.34

To address the need for adjunctive treatment strategies, much emphasis has been placed on more frequent administration of MDA. The success of this approach has been demonstrated with an RCT that compared quarterly MDA for children with annual MDA.15 This trial also supported the result of models that suggest children are the core group for transmission, so that adjunctive treatment for adults is unnecessary.14 Meanwhile, the predictions of other models of more frequent MDA have not shown good agreement with trial data. For instance, one model predicted that a second MDA given soon after the first would be especially efficacious at clearing infection.36 However, this finding has yet to be verified empirically. In fact, three rounds of MDA with high antibiotic coverage in 3 weeks did not prevent infection from returning in the Egyptian arm of the Azithromycin in Control of Trachoma study.17 Additional models predict that repeated biannual distribution will reduce infection more rapidly than annual distribution, but trials have not provided compelling evidence to support this prediction.38–40 Another adjunctive strategy for trachoma control involves improving water, sanitation and hygiene (WASH). Models predict that if WASH measures are able to reduce transmission by at least 10%, there could be benefit.36 However, no trial has yet proven that WASH offers any benefit over annual MDA alone. Of note, some of the studies that failed to show a significant impact of adjunctive treatment may have been underpowered, since they were conducted prior to the wide availability of sensitive nucleic acid amplification tests for identifying current infection.

Limitations of our estimate of control delay include approximations that may bias the estimate of the control delay. First, our analysis ignores how the number of susceptible individuals saturates as the prevalence of infection increases (Figure 2). Although this may be reasonable as we approach control, this approximation overestimates the between-MDA growth of the infected population in high-prevalence settings. That is, the true control delay may actually be shorter than our model’s prediction (as seen by how ‘MDA catch-up’ has slightly lower infection prevalence in later years than ‘MDA as planned’ in the MDA-subcritical panel of Figure 2). In addition, the underlying assumptions of our transmission model ignore many important aspects of trachoma pathophysiology and epidemiology. These include the heterogeneity in transmission due to variable bacterial load, heterogeneity in susceptibility due to variable host immunity and heterogeneity in contact among members of the population. These factors might lead to a control delay longer or shorter than the model prediction. A final consideration is that our model assumes instantaneous delivery of MDA, but logistical programmatic barriers can cause delays in drug delivery within districts. Some of these limitations can be addressed by stochastic models that incorporate more than one state of infection.11,30

The impact of geographic heterogeneity on trachoma control deserves careful consideration, although this issue is not new to the pandemic era. The analyses in this article have been described at the health district level, as this is the geographic level in which infection prevalence surveys are typically acquired. However, there may be districts in which there is significant village-level heterogeneity of transmission within the district. Such heterogeneity would lead to different control delays for different villages within a district. Meanwhile several studies have shown that within a village, exponential growth of infection is typical.33,41 Thus subvillage heterogeneity is probably negligible. This is in accordance with the expected mixing patterns of children, who are primarily responsible for spreading disease.

Despite the limitations of the model, we hope our results can be useful for stakeholders involved in trachoma control (Table 2).42 From a policy perspective, our results provide reassurance that the resumption of trachoma control is feasible. Further work is needed to classify districts as MDA-subcritical versus supercritical, so that district-level distribution of MDA can be optimized. Catch-up treatments may be beneficial in MDA-subcritical districts, but the exact timing will likely not matter. In addition, maintenance of pre-pandemic MDA coverage and efficacy should be prioritized over early resumption of MDA with suboptimal coverage. Meanwhile, supercritical districts will require an alternate treatment strategy to annual MDA.
Table 2. Summary of policy-relevant items for reporting models in epidemiology of neglected tropical diseases

| Policy relevant principle                  | Application to article                                                                 | Location of specific detail                        |
|--------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------|
| Stakeholder engagement                    | Study inspired by NTD Modelling Consortium, which maintains direct communication with the WHO, BMGF, ITI and other stakeholders | Discussion                                          |
| Complete model documentation              | A complete description of our model is provided. Code is available in a GitHub repository | Methods/supplement (available from https://github.com/sblumberg/trachoma—COVID_impact) |
| Complete description of data used         | Model is parameterized by previously published results focused on the transmission dynamics of trachoma | Methods                                             |
| Communicating uncertainty                 | Assumptions of the model that lead to uncertainty in the results are described          | Discussion                                          |
|                                           | Sensitivity analyses for the duration of the infectious period and overall MDA efficacy are presented | Supplemental figure                                  |
| Testable model outcomes                   | An alternative model is presented in this special collection. Given the unprecedented nature of the COVID-19 pandemic, no data are currently available for model validation | See Borlase et al. [11]                             |

BMGF: Bill and Melinda Gates Foundation; ITI: International Trachoma Initiative.

Conclusion

When considering the impact of the COVID-19 pandemic on efforts to control trachoma, districts can be classified as sub-critical, MDA-subcritical or supercritical. In subcritical districts, no significant delay in achieving control goals is anticipated. In MDA-subcritical districts, control after a 1-y program delay can be achieved by either extending the duration of annual MDA distribution or by providing an additional catch-up round of MDA. Meanwhile, supercritical districts will require adjunctive treatments in order to reach control milestones. Although models have endorsed a variety of adjunctive treatments in supercritical districts, quarterly MDA for children remains the only intervention shown to be statistically superior in field trials. The COVID-19 pandemic may offer the opportunity to reassess strategies to achieve trachoma control in these districts.

Supplementary data

Supplementary data are available at Transactions online.

Authors’ contributions: This article arose from a virtual meeting of the NTD Modelling Consortium for which all authors contributed analyses and discussions. SB, TML and TCP wrote the first draft. All authors edited the manuscript and approved the final draft. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.

Acknowledgments: We thank Simon J. Brooker for helping to motivate this research and for his valuable feedback on preliminary work.

Funding: All authors gratefully acknowledge funding of the NTD Modelling Consortium by the Bill and Melinda Gates Foundation (OPP1184344). SB and TML acknowledge National Institutes of Health (NIH) R01 EY025350 and K12 EY031372.

Competing interests: None declared.

Ethical approval: Not required.

Data availability: All input for models are based on cited references.

References

1 World Health Organization. Validation of elimination of trachoma as a public health problem. Available from: http://www.who.int/trachoma/resources/who_htrm_ntd_2016.8/en/ [accessed 6 November 2020].
2 Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Org. 1987;65(4):477–83.
3 World Health Organization Alliance for the Global Elimination of Trachoma. Report of the third meeting of the WHO Alliance for the Global Elimination of Trachoma, Ouarzazate, Morocco, 19–20 October 1998. Available from: https://apps.who.int/iris/handle/10665/65933 [accessed 29 June 2020].
4 Hadfield J, Harris SR, Seth-Smith HMB, et al. Comprehensive global genome dynamics of Chlamydia trachomatis show ancient diversification followed by contemporary mixing and recent lineage expansion. Genome Res. 2017;27(7):1220–9.
5 Mabey DC, Solomon AW, Foster A. Trachoma. Lancet. 2003; 362(9379):223–9.
6 Gambhir M, Basáñez M-G, Turner F, et al. Trachoma: transmission, infection, and control. Lancet Infect Dis. 2007;7(6):420–7.

7 Evans JR, Solomon AW, Kumar R, et al. Antibiotics for trachoma. Cochrane Database Syst Rev. 2019;9:CD001860.

8 Burton M, Habtamu E, Ho D, et al. Interventions for trachoma trichiasis. Cochrane Database Syst Rev. 2015;11:CD004008.

9 WHO validates Myanmar for eliminating trachoma as a public health problem. Available from: https://www.who.int/news/item/17-09-2020-who-validates-myanmar-for-eliminating-trachoma-as-a-public-health-problem [accessed 7 November 2020].

10 Anderson RM, May RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991.

11 Borlase A, et al. Modelling trachoma post 2020: Opportunities for mitigating the impact of COVID-19 and accelerating progress towards elimination. TRSTMH. in press.

12 Solomon AW, Holland MJ, Burton MJ, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet. 2003;362(9379):198–204.

13 Lietman TM, Deiner MS, Oldenburg CE, et al. Identifying a sufficient core group for trachoma transmission. PLoS Negl Trop Dis. 2018;12(10):e0006478.

14 Lietman T, Porco T, Dawson C, et al. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 1999;5(5):572–6.

15 Grassey NC, Ward ME, Ferris S, et al. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis. 2008;2(12):e341.

16 Ray KJ, Lietman TM, Porco TC, et al. When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries. PLoS Negl Trop Dis. 2009;3(6):e458.

17 Bird M, Dawson CR, Schachter JS, et al. Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? J Infect Dis. 2003;187(10):1669–73.

18 Keenan JD, Lakew T, Alemayehu W, et al. Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma. Am J Trop Med Hyg. 2010;82(3):482–7.

19 Koukounari A, Moustaki I, Grassey NC, et al. Using a nonparametric multilevel latent Markov model to evaluate diagnostics for trachoma. Am J Epidemiol. 2013;177(9):1111–8.

20 Liu F, Porco TC, Amza A, et al. Interventions for trachoma trichiasis. Cochrane Database Syst Rev. 2019;9:CD003180.

21 Solomon AW, Foster A, Mabey DCW. Clinical examination versus Chlamydia trachomatis assays to guide antibiotic use in trachoma control programmes. Lancet Infect Dis. 2006;6(1):5–6; author reply, 7–8.

22 Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: are they really telling us? Lancet Infect Dis. 2005;5(5):313–20.

23 Bird M, Dawson C, Miao Y, et al. Does the clinical exam adequately identify ocular chlamydial infection in trachoma? Invest Ophthalmol Vis Sci. 2002;43(13):3061.

24 Keenan JD, Lakew T, Alemayehu W, et al. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. Arch Ophthalmol. 2011;129(4):512–3.

25 Harding-Esch EM, Sillah A, Edwards T, et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Negl Trop Dis. 2013;7(6):e2115.

26 Jimenez V, Gelderblom HC, Flueckiger RM, et al. Mass drug administration for trachoma: how long is not long enough? PLoS Negl Trop Dis. 2015;9(3):e0003610.

27 Wilson N, Goodhew B, Mkocha H, et al. Evaluation of a single dose of azithromycin for trachoma in low-prevalence communities. Ophthalmic Epidemiol. 2019;26(1):1–6.

28 Godwin W, Prada JM, Emerson P, et al. Trachoma prevalence after discontinuation of mass azithromycin distribution. J Infect Dis. 2020;221(Suppl 5):S519–24.

29 Lietman TM, Gebre T, Ayele B, et al. The epidemiological dynamics of infectious trachoma may facilitate elimination. Epidemics. 2011;3(2):119–24.

30 Toor J, Adams ER, Aliee M, et al. Predicted impact of COVID-19 on neglected tropical disease programs and the opportunity for innovation. Clin Infect Dis. 2020; doi: 10.1093/cid/ciaa933.

31 Gao D, Lietman TM, Dong C-P, et al. Mass drug administration: the importance of synchrony. Math Med Biol. 2017;34(2):241–60.

32 Melese M. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA. 2004;292(6):721–5.

33 Lakew T, House J, Hong KC, et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis. 2009;3(2):e376.

34 Lietman TM, Pinsent A, Liu F, et al. Models of trachoma transmission and their policy implications: from control to elimination. Clin Infect Dis. 2018;66(Suppl 4):S725–80.

35 House JI, Ayele B, Porco TC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet. 2009;373(9669):1111–8.

36 Pinsent A, Burton MJ, Gambhir M. Enhanced antibiotic distribution strategies and the potential impact of facial cleanliness and environmental improvements for the sustained control of trachoma: a modelling study. BMC Med. 2016;14:71.

37 Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet. 1999;354(9179):630–5.

38 Melese M, Alemayehu W, Lakew T, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA. 2008;299(7):778–84.

39 Gebre T, Ayele B, Zeihun M, et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet. 2012;379(9811):143–51.

40 Amza A, Kadri B, Nassirou B, et al. A cluster-randomized trial to assess the efficacy of targeting trachoma treatment to children. Clin Infect Dis. 2017;64(6):743–50.

41 Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA. 2004;292(6):721–5.

42 Behrend MR, Basáñez M-G, Hamley JID, et al. Modelling for policy: the five principles of the Neglected Tropical Diseases Modelling Consortium. PLoS Negl Trop Dis. 2020;14(4):e0008033.